强大的IL-2-依赖性抗瘤免疫疗法需要针对瘤特异性CD8的高亲和度IL-2R
Kathryn M LaPorte1, Rosmely Hernandez1, Alicia Santos Savio1
1Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Journal for immunotherapy of cancer
|June 3, 2023
概括
用高剂量的小鼠IL-2/CD25准高亲和度IL-2受体可促进强大的抗瘤免疫和记忆反应,特别是与PD-1阻断相结合,可增强癌症治疗.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
- T细胞治疗学T细胞治疗学
背景情况:
- 目前针对基于IL-2的抗瘤反应的策略通常针对中介亲和IL-2受体,可能限制瘤特异性T效应细胞的参与.
- 瘤抗原特异性T细胞表达高亲和IL-2受体,表明一个潜在的治疗点.
研究的目的:
- 为了评估IL-2生物,小鼠IL-2/CD25的疗效,选择性向高亲和IL-2受体的抗瘤反应.
- 评估这种方法对具有不同免疫性瘤的影响.
主要方法:
- 携带CT26,MC38,B16.F10或4T1瘤的小鼠被单独使用高剂量 (HD) 小鼠 (m) IL-2/CD25或用抗编程细胞死亡蛋白-1 (PD-1) 阻塞治疗.
- 监测瘤生长,并使用多参数流细胞计和功能检测分析瘤微环境 (TME) 中的免疫特征.
主要成果:
- 针对高亲和度IL-2受体的HD mIL-2/CD25显示出强大的抗瘤活性,作为对免疫性瘤的单一疗法,这种效果被抗PD-1联合治疗放大.
- 在CT26瘤模型中用HD mIL-2/CD25治疗导致CD8+:Treg比率升高,瘤特异性CD8+ T效应细胞的频率和功能增强,T细胞耗尽减少.
- 观察到抗瘤记忆反应,表明长期保护的潜力.
结论:
- 针对高亲和度IL-2受体与HD mIL-2/CD25,有或没有PD-1阻塞,有效地促进抗瘤反应.
- 这种策略可能会通过诱导免疫记忆来对瘤复发产生持久的保护.
更多相关视频
07:20Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
14.8K
10:13Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
Published on: May 6, 2019
9.0K
相关概念视频
Tumor Immunotherapy
575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Cytotoxic T Cells-mediated Immune Response
1.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.0K
